FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial
Authors:
- Michelle MierzwaMMMichelle Mierzwa
- Benjamin RosenBRBenjamin Rosen
- Krithika SureshKSKrithika Suresh
- Arjun DineshADArjun Dinesh
- Sam ReganSRSam Regan
- Collin BrummelCBCollin Brummel
- Kakit WongKWKakit Wong
- Keith CasperKCKeith Casper
- Mark PrinceMPMark Prince
- Kelly MalloyKMKelly Malloy
- Andrew ShumanASAndrew Shuman
- Steven ChinnSCSteven Chinn
- 12 December 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (4) , 684-693
Abstract
Purpose: We conducted a phase II multicenter clinical trial to test the hypothesis that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)–based chemoradiation (CRT) dose deescalation would provide noninferior locoregional control compared with historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that human papillomavirus (HPV) circulating tumor DNA (ctDNA) changes during treatment predict locoregional recurrence (LRR). Patients and Methods: Patients with stage I/II p16+ oropharyngeal squamous cell carcinoma were planned to receive radiation 70 Gy in 35 fractions with concurrent weekly carboplatin and paclitaxel. All patients underwent FDG-PET at baseline and at radiation therapy (RT) fraction 10. Patients with ≥50% decrease from baseline to mid-treatment metabolic tumor volume had treatment deescalated to 54 Gy in 27 fractions. The primary endpoint was LRR. Plasma HPV ctDNA was evaluated weekly and in surveillance. Results: Of 84 evaluable patients, 43% met deescalation criteria. With a median follow-up of 37.8 months, 24-month LRR for the entire cohort was 7.8% [90% confidence interval (CI), 2.6%–12.6%], which was less than the 25% rate specified for assessing noninferiority, thereby meeting the primary endpoint. At 1 month after RT, the mean of multiple quality of life measures between the two groups was improved in the 54 Gy cohort, exceeding the minimal clinically important difference threshold. During CRT, week 1 percentage increase in ctDNA relative to baseline was significantly associated with worse loco-regional control (LRC; HR = 1.052 per 10 percentage point increase in ctDNA; 95% CI, 1.007–1.099; P = 0.023) and loco-regional progression-free survival (HR = 1.038; 95% CI, 1.002–1.076; P = 0.035). Conclusions: FDG-PET–based RT dose personalization resulted in promising LRR outcomes in early-stage oropharynx cancer with improved short-term patient-reported outcomes. Furthermore, HPV ctDNA changes early in treatment may predict LRC.Keywords
All Related Versions
Funding Information
- National Cancer Institute (1U01CA183848)
This publication has 34 references indexed in Scilit:
- Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive ChemoradiotherapyJAMA Oncology, 2022
- Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Prospective Phase 2 Study of Radiation Therapy Dose and Volume De-escalation for Elective Neck Treatment of Oropharyngeal and Laryngeal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease RecurrenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus‐associated oropharyngeal squamous cell carcinomaHead & Neck, 2019
- Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Prognostic value of midtreatment FDG‐PET in oropharyngeal cancerHead & Neck, 2016
- Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinomaHead & Neck, 2014
- Quality of Life and Functional Status Measures in Patients With Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 1996